Aramis Biotechnologies
Plant‑based vaccine platform delivering rapid, low‑cost biologics for infectious disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Plant‑based vaccine platform delivering rapid, low‑cost biologics for infectious disease.
Infectious Diseases
Technology Platform
Transient expression of recombinant proteins in Nicotiana plant cells, enabling rapid, scalable, and cost‑effective production of vaccines and biologics.
Opportunities
Rapid, low‑cost vaccine manufacturing can capture market share for seasonal flu and emerging pathogen responses; platform versatility opens doors to therapeutic proteins.
Risk Factors
Regulatory uncertainty for plant‑derived biologics and challenges scaling to commercial volumes could delay market entry.
Competitive Landscape
Competes with traditional egg‑based vaccine manufacturers, mRNA platforms, and other plant‑based biotech firms; differentiation lies in faster production cycles and sustainable processes.